# About MedsGLOW — GLOW Peptide Research Digest Editorial Statement | MedsGLOW > About MedsGLOW: an independent editorial project publishing GLOW peptide research summaries — GHK-Cu, BPC-157, and TB-500 from the peer-reviewed literature. Not a clinic, not a vendor. ## About MedsGLOW MedsGLOW is an independent editorial project that publishes summaries of the peer-reviewed research literature on the GLOW peptide blend — specifically the constituent compounds GHK-Cu, BPC-157, and TB-500. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The name 'MedsGLOW' reflects an editorial position relative to the medicinal and pharmacological research literature on this compound — not a claim that the site offers medical services. The domain name is an editorial framing device, not a designation of clinical status. ## What This Site Publishes MedsGLOW publishes structured summaries of peer-reviewed research on GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (body protection compound 157), and TB-500 (synthetic thymosin beta-4 fragment). Every quantitative claim on this site is cited to a numbered reference in our [GLOW peptide research references](/references) index. Content is organized by compound and topic: mechanism of action, preclinical dosing ranges, clinical data where it exists, and safety observations from published studies. We do not recommend doses for human use. We do not describe the GLOW blend as treating or curing any condition in humans. The GLOW peptide blend as a combined formulation has not been evaluated in a controlled clinical trial. Evidence on this site refers to individual constituent studies. That distinction is material and we maintain it throughout the site. ## Editorial Independence MedsGLOW has no commercial relationship with any peptide manufacturer, vendor, or research organization. We do not accept advertising. We do not earn affiliate revenue from product sales. No person or entity with a commercial interest in any constituent peptide has editorial control over this site's content. We do not link to or recommend specific suppliers or products. We do not carry the GLOW blend or any of its constituents in stock. We do not refer readers to specific vendors. Citations on this site point to PubMed, PubMed Central, and publisher DOIs — primary sources that readers can verify independently. See the [frequently asked questions](/faq) for answers to common research questions, and the [GHK-Cu copper peptide research](/research#ghk-cu) and [BPC-157 mechanism of action](/research#bpc-157) pages for detailed mechanism summaries. ## A Note on Research Context GHK-Cu, BPC-157, and TB-500 are research compounds. BPC-157 and TB-500 are not FDA-approved for any human therapeutic indication and are classified by WADA as prohibited substances under S0 and S2 respectively. GHK-Cu is not WADA-prohibited and is widely used in cosmetic formulations but is not FDA-approved as a drug. This site documents the published research on these compounds. The framing is editorial — a digest of what the studies measured, organized for readers who want to understand the scientific literature. It is not a guide to personal use, not a clinical recommendation, and not an endorsement of any compound for human administration. --- Three signals monitored from the peer-reviewed record — not a clinic, not a vendor, not a reading that prescribes.